Kymriah
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
CAR-T Therapy Associated With Frequent Reports of Cardiopulmonary AEs
Chimeric antigen receptor T-cell therapy—genetically engineered immune cells programmed to identify tumor ...
JANUARY 28, 2022
ALL Has Potential to Relapse After CAR T-Cell Therapy
B-cell acute lymphoblastic leukemia can recur when leukemic cells become resistant to chimeric antigen receptor ...
OCTOBER 26, 2018
CAR T Rx Kymriah Gains Expanded Approval for Some Large B-Cell Lymphomas
The FDA has granted tisagenlecleucel (Kymriah, Novartis) its second indication—the treatment of adults with ...
MAY 4, 2018
Nathan Singh, MD, and David Porter, MD: How I Manage CAR T-Cell Therapy
The human immune system has powerful potential to fight cancer, mediated in large part by T lymphocytes. Autologous ...
FEBRUARY 28, 2018
CAR-T Therapy Kymriah Granted FDA Approval
The FDA has approved the first CAR-T therapy, tisagenlecleucel (Kymriah, Novartis), for the treatment of patients ...
AUGUST 31, 2017